Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

SLDB Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Solid Biosciences Inc.NASDAQ: SLDB

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 109.81M shares rose 65.5% year over year, behind the +94.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 15.9% from the prior quarter. Over 3 fiscal years it compounded at +117.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +65.5% toward the trailing-twelve-month pace of +94.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
109.81M+15.9% QoQ
Last fiscal yearDec 2025
87.5M+114.4% YoY
LTMMar 2026
98.27M+94.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.5%——
1 year+114.4%——
3-year CAGR+117.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
87.5M USD
Year-over-year change
+114.4%
4-year CAGR
+87.2%

Weighted Avg Shares vs competitors

How SLDB compares with its peers on the latest reported figures

  • SLDB's LTM Mar 2026 weighted avg shares of 98.27M shares is the 3rd highest of the 10 companies compared; the peer median is 79.43M shares.
  • Its year-over-year change of +94.3% is the highest of 10, against a peer median of +13.7%.
  • Over three fiscal years its annual growth of +117.4% compares with a peer median of +21.4%.
SLDB Competitors Peer median
Weighted Avg Shares for SLDB and competitors
Company Period LTM YoY 3-year CAGR
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026102.01M +6.4%+6.2%
SLDBSolid Biosciences Inc.LTM Mar 202698.27M +94.3%+117.4%
PTCTPTC Therapeutics, Inc.LTM Jun 202681.93M +5.6%+3.5%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
EWTXEdgewise Therapeutics, Inc.LTM Sep 202679.43M -20.2%+24.3%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
NGNENeurogene Inc.LTM Mar 202620M +14.7%+18.2%
Peer median (excluding SLDB) 79.43M+13.7%+21.4%

Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.62M8.09M000
Cost of Revenue002.58M2.46M1.64M
Gross Profit13.62M8.09M(2.58M)(2.46M)(1.64M)
Gross Margin100.0%100.0%———
Research & Development58.74M78.42M76.56M96.43M140.33M
Selling, General & Admin27.14M28.95M27.75M33.3M38.88M
Operating Expenses85.87M114.55M101.73M127.27M177.57M
Depreciation & Amortization2.96M2.41M2.58M2.46M1.64M
EBITDA(69.22M)(96.87M)(93.43M)(121.9M)(172.69M)
EBITDA Margin-508.3%-1196.8%———
Operating Income(72.25M)(106.45M)(104.32M)(129.73M)(179.21M)
Operating Margin-530.5%-1315.2%———
Interest Income64K2.62M7.14M9.47M9.9M
Interest Expense000340K0
Other Income / Expenses66K20.47M8.3M5.03M4.88M
Income Before Tax(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Pre-Tax Margin-530.0%-1062.3%———
Income Tax Expense00000
Net Income(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Net Margin-530.0%-1062.3%———
EPS (Basic)(10.14)(10.10)(4.83)(3.06)(1.99)
EPS (Diluted)(10.14)(10.10)(4.83)(3.06)(1.99)
Weighted Avg Shares7.12M8.51M19.88M40.82M87.5M
Weighted Avg Shares (Diluted)7.12M8.51M19.88M40.82M87.5M

Solid Biosciences Inc.

NASDAQ:SLDB

Intrinsic Alpha fair value

Locked

Current Price

$6.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.